The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition

EZH2 is a component of polycomb repressive complex 2 (PRC2) and functions as an H3K27 methyltransferase. Loss-of-function mutations in EZH2 are associated with poorer outcomes in patients with myeloproliferative neoplasms (MPNs), particularly those with primary myelofibrosis (MF [PMF]). To determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Sashida, Goro, Wang, Changshan, Tomioka, Takahisa, Oshima, Motohiko, Aoyama, Kazumasa, Kanai, Akinori, Mochizuki-Kashio, Makiko, Harada, Hironori, Shimoda, Kazuya, Iwama, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986523/
https://www.ncbi.nlm.nih.gov/pubmed/27401345
http://dx.doi.org/10.1084/jem.20151121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986523/
https://www.ncbi.nlm.nih.gov/pubmed/27401345
http://dx.doi.org/10.1084/jem.20151121

Ejemplares similares